Wave Life Sciences reports wider-than-expected second quarter loss as revenue misses estimates, while advancing key clinical programs.

Wave Life Sciences reported second quarter 2026 revenue of $2.3 million, down from $8.7 million in the prior-year period, alongside a net loss of $69.4 million, or ($0.34) per share. The company provided updates on its key clinical programs and maintained a strong cash position.

Key Highlights

• The company ended the quarter with $490.6 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into the third quarter of 2028.
• Dosing is now underway in the Phase 2a portion of the INLIGHT trial for its obesity candidate, WVE-007, in individuals with higher BMI.
• An FDA meeting is scheduled for the end of summer 2026 to discuss a potential accelerated approval pathway for WVE-006, its RNA editing candidate for Alpha-1 antitrypsin deficiency (AATD).